ZYME Share Price Performance
US$24.18
12.27 (103.02%)
33.7% undervalued intrinsic discount
US$36.46
Fair Value
Price US$24.18
AnalystConsensusTarget US$36.46
AnalystLowTarget US$30.00
AnalystHighTarget US$55.34
Fair ValueUS$36.46
Share Pricen/a
Zymeworks Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 12 Fair Values set on narratives written by author
ZYME Community Narratives
AN
Fair Value US$36.46 33.7% undervalued intrinsic discount
Analysts Raise Zymeworks Target on Pipeline Progress While Weighing Risks and Valuation Changes
0users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
AN
Fair Value US$30 19.4% undervalued intrinsic discount
ADC And T Cell Engager Setbacks Will Test Reliance On Milestones Yet Offer Long-Term Upside
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$55.34 56.3% undervalued intrinsic discount
Targeted Biologic Therapies Will Serve An Aging World
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Targeted Biologic Therapies Will Serve An Aging World
Key Takeaways Proprietary antibody and ADC platforms, strong partnerships, and AI-driven discovery position Zymeworks for compounding growth in targeted therapies and market expansion. Multiple high-value assets, strategic deals, and efficient development create sustained upside, superior returns, and resilience in a consolidating biopharma landscape.Read more
14
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$55.34
56.3% undervalued intrinsic discount
Fair Value
Profit Margin
29.96%
Future PE
69.6x
Price in 2029
US$67.58
Analysts Raise Zymeworks Target on Pipeline Progress While Weighing Risks and Valuation Changes
Key Takeaways Diversified oncology pipeline, proprietary platforms, and global partnerships position the company for sustained revenue growth, earnings upside, and improved margins through a capital-light model. Advancing clinical milestones, strong R&D productivity, and pharma collaborations increase royalty streams, stability, and long-term asset valuations.Read more
132
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
AN
US$36.46
33.7% undervalued intrinsic discount
Fair Value
Profit Margin
1.42%
Future PE
1.28kx
Price in 2029
US$44.39
ADC And T Cell Engager Setbacks Will Test Reliance On Milestones Yet Offer Long-Term Upside
Catalysts About Zymeworks Zymeworks is a clinical stage biotechnology company focused on antibody drug conjugates, T cell engagers and partnered biologics for oncology and inflammatory diseases. What are the underlying business or industry changes driving this perspective?Read more
3
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$30
19.4% undervalued intrinsic discount
Fair Value
Profit Margin
16.05%
Future PE
175.12x
Price in 2029
US$36.85
Trending Discussion
Recently Updated Narratives
AN
ZYME: Royalty Model Shift And Debt Deal Will Drive Future Upside
Fair Value: US$55.34 56.3% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
ZYME: Royalty Model Will Be Supported By Upcoming HER2 Gastric Cancer Data
Fair Value: US$36.46 33.7% undervalued intrinsic discount
9 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
ADC And T Cell Engager Setbacks Will Test Reliance On Milestones Yet Offer Long-Term Upside
Fair Value: US$30 19.4% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Zymeworks Inc. Key Details
About ZYME
- Founded
- 2003
- Employees
- 264
- CEO
- WebsiteView website
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company’s platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease. It has strategic partnerships and collaborations with Jazz Pharmaceuticals plc; Bristol- Myers Squibb company; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Merck Sharp & Dohme Research GmbH; and Janssen Biotech, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
